| |OCTOBER 20248PM MODI PLEDGES $7.5 MN TO QUAD CANCER MOONSHOT TO BATTLE CERVICAL CANCERINNOCARE PHARMA BAGS CHINESE NOD TO BEGIN CLINICAL TRIAL OF BCL2 INHIBITORPrime Minister Narendra Modi declared assistance of USD 7.5 million in sampling kits, detection kits, and vaccines for nations combatting cervical cancer. Addressing the Cancer Moonshot event in Delaware, Modi stressed India's dedication to worldwide healthcare and its efforts in fighting cervical cancer."An integrated approach of prevention, screening, diagnosis, and treatment is necessary to reduce the burden of cancer. In India, a very cost-effective cervical cancer screening program is being carried out," he said. India has also developed its own vaccine for cervical cancer and is introducing new treatment protocols with the help of Artificial Intelligence.Modi emphasized India's initiatives in offering affordable healthcare with the largest health insurance scheme globally and specialized centers for low-cost medicines. He stated that India plans to donate 40 million vaccine doses for the Indo-Pacific region through GAVI and QUAD programs."I want to thank President Biden for organizing this event. This reflects our shared determination to provide affordable, accessible, and quality health care," Modi added. He also mentioned India's readiness to share its experience and expertise with other countries and its cooperation in radiotherapy treatment and capacity building.The White House-led Cancer Moonshot initiative seeks to advance cancer treatment by promoting collaboration across different sectors. So far, 95 new programs, policies, and resources have been implemented, with input from 170 private companies, non-profits, academic institutions, and patient groups. POInnoCare Pharma, a top biopharmaceutical company specializing in cancer and autoimmune disease treatments, declared the approval of the Investigational New Drug (IND) to carry out a clinical trial of ICP-248, a B-cell lymphoma-2 (BCL2) inhibitor, in conjunction with azacitidine for acute myeloid leukaemia (AML) in China.Acute myeloid leukaemia (AML) is a cancerous blood disease that starts from stem/progenitor cells in the blood and accounts for approximately 80% of cases of acute leukaemia in adults. The likelihood of AML development rises with age and is more prevalent in individuals of middle age and older age. AML is not rare in people under 18 years, making up around 15-20% of childhood leukemia and 80% of leukemia in newborns and babies.BCL2 plays a crucial role in controlling apoptosis pathway, and its atypical expression is linked to the onset of different hematologic cancers. ICP-248 is a new BCL2-selective inhibitor that can be taken orally. Its anti-cancer properties come from specifically blocking BCL2 and reversing the process of programmed cell death.Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare, said, "With strong pipeline in haemato-oncology, InnoCare is dedicated to developing therapeutics with diverse mechanisms of action (MoA) to achieve comprehensive coverage of blood tumour indications. ICP-248 is an important global asset of our company in the field of haematology. We will accelerate clinical development and look forward to bringing greater benefits to patients with haematological malignancies early." POTOP STORIES
< Page 7 | Page 9 >